Furthermore, another study that used the GWAS approach to relate changes in metabolite and protein levels, including CCL2, to intermediate phenotypes found no correlation with COVID-19-related comorbidities (Suhre et al., 2017). This evidence concerns the gene CCL2 and COVID-19.